Business Context and Reporting Period
This Form 8-K Current Report was filed by electroCore, Inc. on March 8, 2019. The filing discloses significant changes in executive leadership, specifically the resignation of the Chief Financial Officer (CFO), the appointment of a new CFO, and a change in the Chief Medical Officer (CMO).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Glenn S. Vraniak (Outgoing CFO): Receiving a $35,000 cash bonus and six months of severance. Equity vesting extended to August 31, 2019. New grant includes options for 18,750 shares and restricted stock valued at $25,000.
- Brian Posner (Incoming CFO): Annual base salary of $325,000 with a target discretionary bonus of up to 40%. Granted options for 105,000 shares at an exercise price of $8.10 per share. Severance terms modified to 12 months with a 1.0 multiple.
- Dr. Peter Staats (Former CMO): New role as Senior Executive Adviser with an annual salary of $210,000 and an equity grant valued at $270,000.
Material Changes Versus Prior Period
The primary material change is the turnover of key financial and medical leadership effective March 2019:
- CFO Transition: Glenn S. Vraniak resigned effective April 1, 2019, with transition services through August 2019. Brian Posner was appointed Vice President of Finance effective March 11, 2019, and CFO effective April 1, 2019.
- CMO Transition: Dr. Tony Fiorino was appointed Chief Medical Officer effective March 22, 2019, replacing Dr. Peter Staats, who transitioned to Senior Executive Adviser of Medical and Government Affairs.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the reliance on Mr. Vraniak to provide transition services through August 2019 to ensure a smooth handover of financial operations.
Investor Verification Checklist
- Verify the exact vesting schedules and exercise prices for the new equity grants issued to Mr. Posner and Dr. Staats.
- Confirm the total cash compensation impact of the $35,000 bonus to Mr. Vraniak and the new salary structures for Mr. Posner and Dr. Staats.
- Review the full text of the Posner Employment Agreement (Exhibit 10.1) for specific non-compete and non-solicitation covenants.
- Monitor the company's subsequent filings for the appointment of a permanent CFO if Mr. Posner's role is interim (though the text implies a permanent appointment).